Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)

<p><strong>Background: </strong>There is no generally accepted methodology for in vivo assessment of antiviral activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment of COVID-19, but whether it has clinically significant antiviral activity...

Full description

Bibliographic Details
Main Authors:	Schilling, WHK, Jittamala, P, Watson, JA, Ekkapongpisit, M, Siripoon, T, Ngamprasertchai, T, Luvira, V, Pongwilai, S, Cruz, CV, Callery, JJ, Boyd, S, Kruabkontho, V, Ngernseng, T, Tubprasert, J, Abdad, MY, Piaraksa, N, Suwannasin, K, Hanboonkunupakarn, P, Hanboonkunupakarn, B, Sookprome, S, Poovorawan, K, Thaipadungpanit, J, Blacksell, S, Imwong, M, Tarning, J, Taylor, WRJ, Chotivanich, V, Sangketchon, C, Ruksakul, W, Chotivanich, K, Teixeira, MM, Pukrittayakamee, S, Dondorp, AM, Day, NPJ, Piyaphanee, W, Phumratanaprapin, W, White, NJ
Other Authors:	PLATCOV Collaborative Group
Format:	Journal article
Language:	English
Published:	eLife Sciences Publications 2023

Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)

Similar Items